Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.
$KALV
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2026 | $27.00 | Buy → Neutral | H.C. Wainwright |
| 1/9/2026 | $32.00 → $35.00 | Buy | Needham |
| 1/6/2026 | $28.00 → $32.00 | Buy | Needham |
| 1/31/2025 | $19.00 | Mkt Outperform | JMP Securities |
| 1/7/2025 | $30.00 | Buy | TD Cowen |
| 12/18/2024 | $22.00 | Buy | BofA Securities |
| 3/11/2022 | $48.00 → $42.00 | Buy | Needham |
| 12/10/2021 | $50.00 → $48.00 | Buy | Needham |
SC 14D9/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
SC 14D9 - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). "These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them," said Ben Palleiko, Chief Executive Officer of KalVista. "Currently, the only FDA-appro
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi's rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi's long-term commitment to people living with rare conditions Transaction expected to close in Q3 2026 Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the "Tran
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro
H.C. Wainwright downgraded KalVista Pharmaceuticals from Buy to Neutral and set a new price target of $27.00
Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously
Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig's appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but remains a member of the Board and continues to serve on the Nominating and Corporate Governance Committee of the Board. The Board also approved Ms. Stuart's appointment to the Compensation Committee of the Board. "I am pleased to welcome Bethany to the Board of Directors of KalVista. Her extensive financial and operational experti
$49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary angioedema (HAE) EKTERLY launched in Japan by partner Kaken Pharmaceutical Co., LTD Company to host conference call today at 8:30am ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending Dece
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company's eight months fiscal year 2025 financial results and provide a corporate update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discov
US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)